Document:

Technology Patent License Agreement dated March 31, 2006

 Exhibit 10.01 
 CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT WAS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH RULE 24b-2, PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED, OMITTED INFORMATION WAS REPLACED WITH ASTERISKS. 
 TECHNOLOGY AND PATENT LICENSE AGREEMENT 
 This Technology and Patent License Agreement (“Agreement”) is entered into by and between Tele Atlas North America, Inc. (“TANA”) and Cobra
Electronics Corporation (“Licensee”) as of this 31 day of March 2006 (“Effective Date”). 
 BACKGROUND 

TANA owns certain technology relating to building a mapping database and accessing the resulting database and certain patents relating to navigation devices. Licensee
develops and manufactures navigation devices that utilize mapping data and wishes to obtain a license to certain TANA technology and patents on the terms and conditions of this Agreement. 
 AGREEMENT 
 1. DEFINITIONS 
 1.1. “Affiliate” with respect to a party means any entity controlling, controlled by, or in common control with such party. 

1.2. “Component Upgrades” means improvements to the *** Software made by TANA after the Effective Date and commercially deployed as
part of an application developer program. 
 1.3. “*** Software” means the software components, libraries and *** listed on
Exhibit A. 
 1.4. “Field of Use” ***. 
 1.5. “*** Technology” means the *** Software in source code form, the related engineering documentation delivered to Licensee, the *** Format Technology and the know-how and technical information
related to the foregoing owned by TANA as of the Effective Date and the Component Upgrades delivered to Licensee after the Effective Date. 
 1.6. “*** Format Technology” means the TANA proprietary technology enabling the conversion of raw map data to the TANA *** format. 
 1.7. “Patent Licensed Unit” means any product which, but for the license granted herein, would infringe a claim in the Patent Rights. 
 1.8. “Patent Rights” means the patents and patent applications listed on Exhibit B, all divisions and substitutions thereof; including
any extensions, reissues, and re-examinations, and all foreign counterparts owned by TANA and with respect to which TANA has the right to grant licenses of the scope granted herein. 

 1.9. “Royalties” means royalties payable in respect of Technology Licensed Units and
Patent Licensed Units. 
 1.10. “***” means the *** Technology or derivatives thereof in human readable form. 
 1.11. “TANA Competitor” means an entity identified on Exhibit D as updated from time to time by TANA in its reasonable discretion and
Affiliates of such entities. 
 1.12. “Technology Licensed Unit” means any product that utilizes, incorporates, is based on
or was derived using any *** Technology or derivative thereof. 
 1.13. “Technology Royalty Term” means that period
beginning on the date the first royalty payment in respect of a Technology Licensed Unit accrues and ending *** from that date. 
 2. LICENSE GRANT

 2.1. Technology License. Subject to the terms and conditions of this Agreement, TANA hereby grants to Licensee a ***
license, ***, to the *** Technology for internal use to develop software applications for use and distribution solely in object code form and, during the Technology Royalty Term, solely for use in the Field of Use. ***. For clarification, Licensee
may not provide derivative works to third parties in ***. Licensee shall not provide any derivative works to a TANA Competitor. In the event that Licensee desires to expand the Field of Use to include products developed and promoted for commercial
use the parties will negotiate in good faith to agree on terms applicable to such use. The *** data deliverables identified on Exhibit A (“*** Data”) are provided solely for internal development and testing purposes, may not be
commercialized or distributed in any manner and shall be returned to TANA (or destroyed at TANA’s request) after *** from the Effective Date. 
 2.2. Restrictions. Licensee may not distribute or sublicense the *** Software. ***. 
 2.3. Patent
License. Subject to the terms and conditions of this Agreement, TANA hereby grants to Licensee a *** license, ***, under the Patent Rights to make, have made, import, use, offer for sale and sell Patent Licensed Units in the Field of Use.

 2.4. Reservation of Rights. All rights not expressly granted herein are reserved to TANA and no other rights shall be
created by implication, estoppel or otherwise. Nothing will restrict TANA’s rights with respect to the Patent Rights or rights to use or sublicense the *** Software or *** Technology in whole or part. 
 2.5. Covenant Not to Sue. In partial consideration for the rights and obligations contained herein, Licensee agrees not to enforce against
TANA or its Affiliates any patent right owned or controlled by Licensee which TANA or its Affiliates may infringe in practicing any invention claimed in the Patent Rights. 
  

 2 

 3. DELIVERY AND ENGINEERING SUPPORT. 
 3.1. Technology Transfer. Promptly after the Effective Date, TANA will deliver to Licensee the tangible embodiments of the *** Technology. TANA will provide a total of *** man-weeks of engineering
support to transfer the *** Technology to Licensee without charge as follows: *** engineering man-week will be provided to Licensee after the delivery of all *** Software components and documentation; *** engineering man-weeks will be provided to
Licensee beginning one month after the delivery of all identified components and may be spread out over the succeeding four months. For clarification purposes a “man-week” shall mean forty (40) working hours. Licensee will identify a
team responsible for accepting the technology transfer and the parties will agree on times, locations and scheduling. Any additional engineering support beyond the *** engineering man-weeks must be agreed upon in writing, set forth in a statement of
work and will be billable to Licensee at a rate of $*** per hour. 
 3.2. Component Upgrades. TANA may at its discretion
provide Component Upgrades to Licensee from time to time in executable form and source code form during the Technology Royalty Term, ***. 
 3.3. Optional Custom Engineering Services. TANA has proposed to provide professional services to Licensee to complete the software development projects described on Exhibit C. If Licensee elects to engage TANA for such
services, or for other services related to the *** Technology, the parties will be obligated to proceed only pursuant to one or more mutually agreed upon statements of work to be executed by both parties, referencing this Agreement and setting forth
in reasonable detail the terms and conditions with respect to such services. If no specific terms are set forth in the applicable statement of work with respect to the ownership of deliverable items under such statement of work, then such
deliverable items shall be deemed to be included within the definition of *** Technology and will be delivered in ***. 
 4. FEES AND PAYMENT

 4.1. *** License Fee. In consideration of the rights granted herein, Licensee shall pay to TANA a *** license fee of
$*** to be invoiced in March 2006 and payable as follows: 
 Payment of $*** to be paid within 30 days from the invoice date

 Payment of $*** to be paid within 90 days from the invoice date 
 4.2. Technology Royalties. In consideration of the rights granted in Section 2.1, during the Technology Royalty Term, Licensee shall
pay to TANA a *** each Technology Royalty Unit leased, sold, licensed, distributed or otherwise transferred or deployed for commercial use by Licensee. ***. For clarification,”Year 1”, “Year 2” etc., refers to each 12-month
period succeeding the date on which the first Technology Unit Royalty payment accrues. 
  

 3 

											
	 Royalty per Technology Licensed Unit
	    	***	    	***	    	***	    	***	    	***
	 *** royalty component
	    	$***/unit	    	$***/unit	    	$***/unit	    	$***/unit	    	$***/unit
	 *** royalty component
	    	$***/unit	    	$***/unit	    	$***/unit	    	$***/unit	    	$***/unit

 4.3. Patent Royalty. In consideration of the rights granted in Section 2.3,
Licensee will pay *** for each Patent Licensed Unit leased, sold, licensed, distributed or otherwise transferred or deployed for commercial use by Licensee. The foregoing royalties are payable until ***. For clarification, to the extent that a
particular unit is both a Technology Licensed Unit and a Patent Licensed Unit, both Royalties will be due for such unit. 
 4.4.
Payment. ***. Royalties are payable quarterly within 30 days from the end of each calendar quarter. Royalties accrue at the time the Patent Licensed Unit or Technology Licensed Unit is shipped or transferred or deployed for commercial
use, as applicable, or at the time the transaction is booked in accordance with GAAP, if earlier. Royalty payments otherwise due may be offset to account for units for which a Royalty has previously been paid but which are returned to Licensee and
for which Licensee has paid a refund to the purchaser. 
 4.5. Taxes. All Royalties required to be paid to TANA pursuant to
this Agreement are to be paid without deduction on account of any taxes of any kind including withholding taxes. Any taxes applicable to the transactions contemplated herein shall be the sole responsibility of Licensee, other than US taxes due on
the net income of TANA. 
 4.6. Reports. Within thirty (30) days after the end of each calendar quarter Licensee shall
provide TANA with a report in reasonable detail stating in each such report, by country, the number and description of each Technology Royalty Unit and Patent Licensed Unit leased, sold, licensed, distributed or otherwise transferred or deployed for
commercial use or booked, as applicable, during such quarter, units returned for refunds, and the calculation of amounts due to TANA. Concurrently with the making of such reports, Licensee shall pay TANA the Royalties due. 
 4.7. Records; Inspection. Licensee shall keep complete, true and accurate books of account and records for the purpose of determining the
Royalty amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of Licensee for at least three (3) years following the end of the calendar quarter to which they pertain and will be open for
inspection during such period by a representative of TANA for the purpose of verifying the royalty reports and payments. Such inspections shall be made during ordinary business hours. The representative may be obliged to execute a reasonable
confidentiality agreement prior to commencing any such inspection. Inspections conducted under this Section shall be at the expense of TANA, unless an underpayment exceeding *** of the amount stated for any period covered by the inspection is
identified, in which case all costs relating to the inspection and any unpaid amounts will be paid by Licensee, with interest from the date such amounts were due. Any and all information gathered during such inspections shall be deemed to be
Confidential Information as defined in Section 8 of this Agreement whether or not so designated at the time of the inspection. 
  

 4 

 5. REPRESENTATIONS AND WARRANTIES 
 5.1. Representations and Warranties. TANA represents and warrants that: (i) it is the sole and exclusive owner of all right, title and interest in the Patent Rights; (ii) except with respect to
the items identified on Exhibit A as open source, it has independently developed the *** Technology; (iii) except with respect to claims identified on Exhibit E, use of the items identified on Exhibit A as comprising the commercially
distributed version of the *** Software in accordance with the user manuals applicable to such software does not infringe the intellectual property rights of any third party. 
 5.2. Disclaimer. Nothing in this Agreement is or shall be construed as: 
 a) A warranty or representation by TANA as to the validity or scope of any claim or patent within the Patent Rights; 
 b) Except as provided in Section 5.1 of this Agreement, a warranty or representation that anything made, used, sold, or otherwise disposed of under
any license granted in this Agreement is or will be free from infringement of any patent rights or other intellectual property right of any third party; 
 c) An obligation to bring or prosecute actions or suits against third parties for infringement of any of the Patent Rights or misappropriation of any *** Technology;or 
 d) Granting by implication, estoppel, or otherwise any licenses or rights under patents or other rights of TANA or third parties, regardless of whether
such patents or other rights are dominant or subordinate to any patent within the Patent Rights. 
 5.3. No Warranties. EXPCEPT
AS EXPRESSLY SET FORTH ABOVE IN SECTION 5.1, TANA AND ITS LICENSORS AND SUPPLIERS GRANT NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUE OR OTHERWISE, AND TANA AND ITS LICENSORS AND SUPPLIERS SPECIFICALLY DISCLAIM
ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF THE PATENT RIGHTS OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. 
 6. INDEMNIFICATION 
 6.1. By TANA. TANA
agrees to indemnify, defend and hold Licensee and its directors, officers and employees harmless from and against any and all liabilities, costs and expenses (including, without limitation, attorneys and professional fees and related costs of
litigation), resulting from a claim brought by a third party to the extent such claim arises directly out of a breach by TANA of the representations and warranties set forth in Section 5.1 above (a “Claim”). For clarification, and
notwithstanding anything to the contrary in this Agreement, TANA has no liability to the extent that a Claim is based upon alteration or modification by Licensee of any *** Technology supplied hereunder or implementation of the Patent Rights.

  

 5 

 6.2. By Licensee. Except to the extent of TANA’s obligation to indemnify Licensee in
accordance with Section 6.1 above, Licensee agrees to indemnify, defend and hold TANA and its licensors, suppliers, directors, officers and employees harmless from and against any and all liabilities, costs and expenses (including, without
limitation, attorneys and professional fees and related costs of litigation), resulting from a claim brought by a third party to the extent such claim arises directly out of (i) the development, possession, manufacture, use, sale or other
disposition of Technology Licensed Units or Patent Licensed Units, or (ii) any breach of this Agreement by Licensee. 
 6.3.
Conditions. Each party’s obligation to indemnify as specified in this Section 6 will be conditioned on the indemnified party notifying the indemnifying party promptly in writing of the claim and giving the indemnifying party
full authority, information, and assistance for the defense and settlement thereof. The indemnified party may choose to assist the indemnifying party in the defense of such claim at its own expense. 
 7. Term and Termination. 
 7.1. Term.
Unless and until earlier terminated as permitted herein, this Agreement shall become effective on the Effective Date and expire on the later of: ***. 
 7.2. Termination for Breach. Either party may terminate this Agreement upon prior written notice in the event that the other party breaches a material term of this Agreement and fails to cure such breach
within 30 days from written notice to cure by the non-breaching party. Notwithstanding the above, in the case of a failure to pay any amount due hereunder the period for cure of any such default following notice thereof shall be ten (10) days
and, unless payment is made within such period, the termination shall become effective at the end of such period. 
 7.3.
Termination for Insolvency. Either party may terminate this Agreement upon notice in the event the other party (a) files or has filed against it voluntary or involuntary proceedings instituted under any bankruptcy or insolvency law,
or a receiver or custodian is appointed for such party, or proceedings are instituted for corporate dissolution of such party, and such proceedings, if involuntary, have been dismissed within sixty (60) days after the date of filing, or
(b) if such party makes an assignment for the benefit of creditors. 
 7.4. Effect of Termination. 
 a) Accrued Rights and Obligations. Expiration or termination of this Agreement for any reason shall not release any party hereto from any liability
which has already accrued to the other party or which is attributable to a period prior to such termination nor preclude either party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of
this Agreement. It is understood and agreed that monetary damages may not be a sufficient remedy for any breach of this Agreement and that the non-breaching party may be entitled to injunctive relief as a remedy for any such breach. Such remedy
shall not be deemed to be the exclusive remedy for any such breach of this Agreement, but shall be in addition to all other remedies available at law or in equity. 
  

 6 

 b) Return of Confidential Information. Upon any termination of this Agreement, each party shall
promptly return to the other party all Confidential Information belonging to such other party. 
 c) Licenses. All licenses granted
hereunder shall terminate upon the termination of this Agreement, however, except in the event of termination by TANA for Licensee’s failure to make payments due hereunder, Licensee shall be allowed a period not to exceed *** during which it
may fulfill orders, sell off, or otherwise dispose of inventories which had been ordered, manufactured or were in the process of manufacture as of the date of termination, subject to the terms and conditions of this Agreement. 
 d) End Users. Provided that applicable royalties have been paid with respect to such units, end users or customers of Licensee who have leased or
purchased Technology Licensed Units or Patent Licensed Units may continue to use such units without challenge from TANA. 
 7.5.
Survival. Sections 1, 4.5, 4.6, 4.7, 5.1, 5.3, 6, 7.4, 7.5, 8, 9 and 10.2 through 10.14 of this Agreement shall survive the expiration or termination of this Agreement for any reason. The license rights granted in Section 2 of this
Agreement shall survive expiration (but not termination except to the extent permitted in Section 7.4 (c)) of this Agreement, subject to the right of TANA to terminate for breach (pursuant to Section 7.2 which shall survive for such
purpose) of any surviving Sections. 
 8. CONFIDENTIALITY 
 8.1. “Confidential Information” means any information, market data, strategies, pricing information, customer lists, technical data, or know-how which the disclosing party treats as
confidential and which the receiving party knows or should know is so treated by the disclosing party. Notwithstanding anything to the contrary herein, Licensee acknowledges that the *** Technology constitutes valuable trade secrets of TANA and
shall remain the Confidential Information of TANA at all times. Confidential Information does not include information that: (i) is in the possession of the receiving party at the time of disclosure; (ii) becomes part of the public
knowledge or literature, not as a result of any inaction or action of the receiving party; (iii) is approved by the disclosing party, in writing, for release; or (iv) becomes available to the receiving party from a third party source not
bound by any obligation of confidentiality with respect to such information. Each party agrees not to use or disclose the Confidential Information disclosed to it by the other party for any purpose except to fulfill its obligations or exercise its
rights under this Agreement. Each party agrees that it will take all reasonable measures to protect the secrecy of and avoid disclosure or use of Confidential Information of the other in order to prevent it from falling into the public domain or the
possession of persons other than those persons authorized hereunder to have any such information, which measures shall include at least a reasonable degree of care. 
 8.2. Permitted Disclosures. Either party may provide a copy of this Agreement to persons and/or entities who are under obligations of confidentiality substantially similar to those set forth in this
Agreement to the extent necessary to comply with legal disclosure obligations in connection with due diligence review of such party relating to potential financing transactions, 

  

 7 

 
acquisitions, bank loans and similar transactions. Either party may also provide a copy of this Agreement to: (i) the party’s public accounting
firm in connection with the preparation or review of financial or tax information, and (ii) to the party’s outside legal advisors in connection with obtaining legal advice relating to this Agreement, the relationship established by this
Agreement or any related matters. Either party may disclose the existence or contents of this Agreement as required by any public regulatory body such as, but not limited to, the Securities and Exchange Commission. In the event of such required
public disclosure, each party may request to review the planned disclosure of the other party prior to the party’s disclosure. 
 8.3. Public Announcement. Neither Licensee nor TANA shall make any public announcement or public statement with respect to the existence or the terms of this Agreement or the transactions contemplated hereby without the prior
written consent of the other party as to the contents of such announcement or statement. 
 9. LIMITATION OF LIABILITY 
 IN NO EVENT SHALL TANA BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT OR CONSEQUENTIAL DAMAGES OF ANY KIND EVEN IF ADVISED OF THE POSSIBLITY OF SUCH DAMAGES,
ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT. EXCEPT WITH RESPECT TO AMOUNTS PAYABLE TO THIRD PARTIES IN CONNECTION WITH A CLAIM UNDER SECTION 6, IN NO EVENT WILL TANA’S LIABILITY FROM ANY AND ALL CAUSES RELATING TO THE SUBJECT MATTER OF
THIS AGREEMENT EXCEED THE AMOUNTS PAID HEREUNDER DURING THE TWENTY-FOUR MONTH PERIOD IMMEDIATELY PRECEEDING SUCH CLAIM. LICENSEE AGREES THAT TANA’S LICENSORS AND SUPPLIERS SHALL HAVE NO LIABILITY IN CONNECTION WITH THIS AGREEMENT. 

10. General 
 10.1. Assignment.
Licensee may not assign this Agreement to any third party without the prior written consent of TANA, which shall not be unreasonably withheld, except that such consent shall not be required for an assignment in connection with a merger or sale of
substantially all the business or assets to which this Agreement relates, provided the acquiring entity assumes all obligations hereunder and Licensee remains liable for all obligations arising prior to the assignment. Notwithstanding the foregoing,
Licensee may not assign this Agreement under any circumstances to a TANA Competitor. The license rights granted herein may be assigned to an Affiliate of Licensee without the prior consent of TANA so long as Licensee remains liable as a guarantor
for such Affiliate’s performance, provided that such Affiliate is not a TANA Competitor. This Agreement will bind and inure to the benefit of the parties and their respective successors and permitted assigns. 
 10.2. Notice. Any notice provided for or permitted under this Agreement must be in writing and will be treated as having been given when
(a) delivered personally, (b) sent by confirmed facsimile, or (c) sent by nationally recognized commercial overnight courier with written verification of receipt, to the party to be notified, at the address set forth below, or at such
other place of which the other party has been notified in accordance with the provisions of this Section. 
  

 8 

			
	 If to Licensee:
  
	  	
	     Bill Chamberlain (Jim Bazet)                        
     6500 West Cortland Street
     Chicago, IL 60707
	  	 Pran Jha, Esq.
 Sidley Austin LLP
 One South Dearborn
 Chicago, Illinois 60603

  

			
	  If to TANA:	 	General Counsel
		 	Tele Atlas
		 	11 Lafayette Street
		 	Lebanon, NH 03766-1445
		 	Fax: (603) 643-0315

 Such notice will be treated as having been received upon the earlier of actual receipt or three (3) days
after posting. 
 10.3. Waiver. No term or provision hereof will be considered waived by either party, and no breach excused by
either party, unless such waiver or consent is in writing signed on behalf of the party against whom the waiver is asserted. No consent by either party to, or waiver of, a breach by either party, whether express or implied, will constitute a consent
to, waiver of, or excuse of any other, different, or subsequent breach by either party. 
 10.4. Severability. If any term of
this Agreement is held invalid or unenforceable for any reason, such term or the remainder of such term shall be amended to achieve as closely as possible the economic effect of the original term and all other terms shall continue in full force and
effect. 
 10.5. Marking. Licensee agrees to affix to all applicable products or product packaging made or sold by it under the
terms of this Agreement the number of each patent of the Licensed Patents claiming an invention embodied in such product or, alternatively, a list of all Licensed Patents in a manner which is adequate to provide notice under the terms of 35 United
States Code Section 287. 
 10.6. Governing Law. This Agreement shall be governed by and construed under the laws of the
United States and the State of California as applied to agreements entered into and to be performed entirely within California between California residents. 
 10.7. Arbitration. The parties agree that any dispute, claim or controversy arising out of this Agreement shall be finally settled by binding arbitration under the rules of the American Arbitration
Association (“AAA”) by a single arbitrator shall be selected according to AAA rules. The arbitrator shall have the power to enter any award that could be entered by a Judge of the Superior Court of the State of California sitting without a
jury, and only such power. The arbitration award may be enforced in any court having jurisdiction over the parties and the subject matter of the arbitration. Notwithstanding the foregoing, either party may file suit in any court having jurisdiction
over the parties and the subject matter of the dispute if necessary to seek a temporary restraining order and/or preliminary injunction to enjoin the other party from misappropriating, or infringing, any intellectual property right of the moving
party, or to enforce any arbitration award, and the parties consent to the jurisdiction of the state and federal courts located in the State of California for such purposes. 
  

 9 

 10.8. Force Majeure. Neither party will be liable for any failure or delay in performance
under this Agreement to the extent due to causes beyond the reasonable control of such party. In the event of the happening of such a cause, the party whose performance is so affected will give prompt, written notice to the other party, stating the
period of time the same is expected to continue and shall use commercially reasonable efforts to cure the delay. Such delay will not be excused under this Section for more than ninety (90) days. 
 10.9. Entire Agreement. This Agreement, including all exhibits to this Agreement, constitutes the entire agreement between the parties with
respect to the subject matter hereof and supersedes all prior or simultaneous representations, discussions, negotiations, and agreements with respect thereto, whether written or oral. 
 10.10. Amendment. This Agreement may be amended or supplemented only by a writing that is signed by duly authorized representatives of both
parties. 
 10.11. Relationship of the Parties. The parties to this Agreement are independent contractors. There is no
relationship of agency, partnership, joint venture, employment, or franchise between the parties. Neither party has the authority to bind the other or to incur any obligation on its behalf. 
 10.12. Construction of Agreement. This Agreement has been negotiated by the respective parties and their attorneys and the language shall
not be construed for or against any party. The titles and headings herein are for reference purposes only and shall not in any manner limit the construction of this Agreement, which shall be considered as a whole. 
 10.13. Certain Usages. Unless the context of this Agreement clearly requires otherwise, references to the plural include the singular, and
the singular includes the plural. The term “including” means “including, but not limited to.” “All” includes “any” and “any” includes “all.” “Or” is not exclusive. The term
“person” includes natural persons and all forms of legal entities. 
 10.14. Counterparts. This Agreement may be
executed in two counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument. If this Agreement is executed in counterparts, no signatory hereto shall be bound until both the
parties named below have duly executed and delivered to the other party a counterpart of this Agreement. 
  

									
	“TANA”	 		 	“Licensee”
					
	By	 	 /s/ Ilse R. Ramsey
	 		 	By	 	 /s/ James R. Bazet

	Name:	 	Ilse R. Ramsey	 		 	Name:	 	James R. Bazet
	Title:	 	VP, Finance & Administration	 		 	Title:	 	President & CEO
	Date	 	3/31/2006	 		 	Date	 	3/31/2006

  

 10 

 Exhibit A 
 Deliverables 
 *** 

 Exhibit B 
 Licensed Patents 
 *** 

 Exhibit C 
 Proposed Projects for Professional Services 
 *** 

 Exhibit D 
 TANA Competitors 
 *** 

 Exhibit E 
 Disclosure Of Claims 
 *** 
 CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT WAS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH RULE 24b-2, PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, OMITTED
INFORMATION WAS REPLACED WITH ASTERISKS.Employment Agreement

 Exhibit 10.1 
 EMPLOYMENT AGREEMENT 
 (Ed Kessig) 
 THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into this 10th day of May 2005 by and between Auxilium Pharmaceuticals, Inc. (the
“Company”) and Ed Kessig (“Executive”). 
 WHEREAS, the Company desires to employ Executive, and Executive desires to be
employed by the Company upon the terms and conditions hereinafter set forth; 
 NOW, THEREFORE, the parties hereto, intending to be legally
bound, hereby agree as follows: 
 1. Employment. The Company hereby agrees to employ Executive, and Executive hereby accepts such employment and
agrees to perform Executive’s duties and responsibilities, in accordance with the terms, conditions and provisions hereinafter set forth. This Agreement shall be effective as of May 10, 2005 (the “Effective Date”) and shall continue
until terminated in accordance with Section 2 hereof. Nothing in this Agreement shall be construed as giving Executive any right to be retained in the employ of the Company, and Executive specifically acknowledges that Executive shall be an
employee-at-will of the Company, and thus subject to discharge at any time by the Company with or without cause and without compensation of any nature except as provided in Section 2 below. 
 1.1 Duties and Responsibilities. Commencing on the Effective Date, Executive shall serve as the Vice President, Field Sales of the Company and
shall perform all duties and accept all responsibilities incident to such position as may be reasonably assigned to Executive by the Company’s Board of Directors (the “Board”) or by the Chief Executive Officer of the Company.

 1.2 Extent of Service. Executive agrees to use Executive’s best efforts to carry out Executive’s duties and
responsibilities under Section 1.1 hereof and, consistent with the other provisions of this Agreement, to devote substantially all of Executive’s business time, attention and energy thereto. The foregoing shall not be construed as
preventing Executive from making investments in other businesses or enterprises, provided that Executive agrees not to become engaged in any other business activity which, in the reasonable judgment of the Board, is likely to interfere with
Executive’s ability to discharge Executive’s duties and responsibilities to the Company. 
 1.3 Base Salary. For all the
services rendered by Executive hereunder, the Company shall pay Executive a base salary (“Base Salary”) at the annual rate of $215,000, payable bi-weekly in installments at such times as the Company customarily pays its other senior level
executives. Executive’s Base Salary shall be reviewed annually for appropriate increases by the Board or compensation committee pursuant to the normal performance review policies for senior level executives. 
 1.4 Incentive Compensation. The Executive shall participate in short-term and long-term incentive programs established by the Company for its
senior level executives generally, at levels determined by the Board or the Chief Executive Officer. Executive’s incentive 
  

 1 

 compensation shall be subject to the terms of the applicable plans and shall be determined based on Executive’s
individual performance and Company performance as determined by the Board or the Chief Executive Officer. Executive’s bonus eligibility for 2005 shall be 40% of his base salary, subject to achievement of goals to be mutually agreed upon by
Executive and the Chief Executive Officer. 
 1.5 Retirement and Welfare Plans. Executive shall participate in employee retirement and
welfare benefit plans made available to the Company’s senior level executives as a group or to its employees generally, as such retirement and welfare plans may be in effect from time to time and subject to the eligibility requirements of the
plans. Nothing in this Agreement shall prevent the Company from amending or terminating any retirement, welfare or other employee benefit plans or programs from time to time as the Company deems appropriate. 
 1.6 Reimbursement of Expenses; Vacation. Executive shall be provided with reimbursement of reasonable expenses related to Executive’s
employment by the Company on a basis no less favorable than that which may be authorized from time to time for senior level executives as a group, and shall be entitled to four (4) weeks of vacation and three (3) personal days in
accordance with the Company’s pay for time not worked policies. 
 2. Termination. Executive’s employment shall terminate upon the
occurrence of any of the following events: 
 2.1 Termination Without Cause Before A Change of Control. 
 (a) The Company may remove Executive at any time without Cause (as defined in Section 2.9) from the position in which Executive is employed hereunder
upon not less than 30 days’ prior written notice to Executive. 
 (b) If Executive’s employment terminates as described in
subsection (a) above and Executive executes and does not revoke a written release upon such removal, in a form provided by the Company, of any and all claims against the Company and all related parties with respect to all matters arising out of
Executive’s employment by the Company, or the termination thereof (the “Release”), Executive shall be entitled to receive the following severance compensation, as long as Executive complies with the terms of Sections 4, 5, 6 and 7
below: 
 (i) Executive shall receive severance payments in an amount equal to 0.75 times Executive’s annual Base Salary at the rate in
effect at the time of Executive’s termination. The severance amount shall be paid in equal monthly installments over the nine-month period following Executive’s termination of employment (the “Severance Period”). Monthly payments
shall commence within 30 days after the effective date of the termination (or the end of the revocation period for the Release, if later). 
 (ii) During the Severance Period, Executive shall continue to receive the medical coverage in effect at the date of Executive’s termination (or generally comparable coverage) for Executive and, where applicable, Executive’s spouse
and dependents, as the same may be changed from time to time for employees generally, as if Executive had continued in employment during such period; or, as an alternative, the Company may elect to pay Executive cash in lieu of such coverage in an
amount equal to Executive’s COBRA cost of continuing such 
  

 2 

 coverage (less any required employee payments calculated as if Executive had continued to be an employee), where such
coverage may not be continued (or where such continuation would adversely affect the tax status of the plan pursuant to which the coverage is provided). The COBRA health care continuation coverage period under Section 4980B of the Internal
Revenue Code of 1986, as amended (the “Code”), shall run concurrently with the Severance Period. 
 (iii) Executive shall receive
any benefits accrued in accordance with the terms of any applicable benefit plans and programs of the Company. 
 (iv) Executive agrees that
if Executive fails to comply with Section 4, 5, 6 or 7 below, all payments under this Section 2.1 shall immediately cease. 
 2.2
Termination Without Cause; Resignation for Good Reason After A Change of Control. 
 (a) If a Change of Control occurs and the Company
terminates Executive’s employment without Cause at any time upon or after a Change of Control or Executive resigns for Good Reason (as defined in Section 2.9) upon or at any time during the one-year period following the Change of Control,
this Section 2.2 shall apply. 
 (b) If Executive’s employment terminates as described in subsection (a) above and Executive
executes and does not revoke a Release, Executive shall be entitled to receive the following severance compensation, as long as Executive complies with the terms of Sections 4, 5, 6 and 7 below: 
 (i) Executive shall receive a lump sum severance payment in an amount equal to (A) .75 times Executive’s annual Base Salary at the rate in
effect at the time of Executive’s termination, plus (B) .75 times Executive’s average annual bonus paid by the Company to Executive for the two fiscal years preceding Executive’s termination of employment. The payment shall be
made within 30 days after the effective date of the termination of employment (or the end of the revocation period for the Release, if later). 
 (ii) During the nine-month period following Executive’s termination of employment (the “Severance Period”), Executive shall continue to receive the medical coverage in effect at the date of Executive’s termination (or
generally comparable coverage) for Executive and, where applicable, Executive’s spouse and dependents, as the same may be changed from time to time for employees generally, as if Executive had continued in employment during such period; or, as
an alternative, the Company may elect to pay Executive cash in lieu of such coverage in an amount equal to Executive’s COBRA cost of continuing such coverage (less any required employee payments calculated as if Executive had continued to be an
employee), where such coverage may not be continued (or where such continuation would adversely affect the tax status of the plan pursuant to which the coverage is provided). The COBRA health care continuation coverage period under
Section 4980B of the Code, shall run concurrently with the Severance Period. 
 (iii) All outstanding stock options held by Executive
at the date of Executive’s termination of employment shall become fully exercisable on the date of termination and all stock awards held by Executive at the date of Executive’s termination of employment shall become fully vested and
exercisable as of the date of termination. 
  

 3 

 (iv) Executive shall receive any benefits accrued in accordance with the terms of any applicable benefit
plans and programs of the Company. 
 (c) Executive agrees that if Executive materially breaches Section 4, 5, 6 or 7 below, all
payments under this Section 2.2 shall immediately cease. 
 2.3 Increase in Payments Upon a Change of Control. 
 (a) Anything in this Agreement to the contrary notwithstanding, in the event that it shall be determined that any payment or distribution by the Company
to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (a “Payment”), would constitute an “excess parachute payment” within the meaning of
Section 280G of the Code, the Company shall pay to Executive an additional amount (the “Gross-Up Payment”) such that the net amount retained by Executive after deduction of any excise tax imposed under Section 4999 of the Code,
and any federal, state and local income tax, employment tax and excise tax imposed upon the Gross-Up Payment, shall be equal to the Payment. For purposes of determining the amount of the Gross-Up Payment, unless Executive specifies that other rates
apply, Executive shall be deemed to pay federal income tax and employment taxes at the highest marginal rate of federal income and employment taxation in the calendar year in which the Gross-Up Payment is to be made and state and local income taxes
at the highest marginal rate of taxation in the state and locality of Executive’s residence on Executive’s termination date, net of the maximum reduction in federal income taxes that may be obtained from the deduction of such state and
local taxes. 
 (b) All determinations to be made under this Section 2.3 shall be made by the Company’s independent public
accountant immediately prior to the Change of Control or by another independent public accounting firm mutually selected by the Company and Executive before the date of the Change of Control (the “Accounting Firm”), which firm shall
provide its determinations and any supporting calculations both to the Company and Executive within 20 days after Executive’s termination date. Any such determination by the Accounting Firm shall be binding upon the Company and Executive.
Within 10 days after the Accounting Firm’s determination, the Company shall pay the Gross-Up Payment to Executive. 
 (c) All of the
fees and expenses of the Accounting Firm in performing the determinations referred to in this Section 2.3 shall be borne solely by the Company. The Company agrees to indemnify and hold harmless the Accounting Firm from any and all claims,
damages and expenses resulting from or relating to its determinations pursuant to this Section 2.3, except for claims, damages or expenses resulting from the gross negligence or willful misconduct of the Accounting Firm. 
 2.4 Voluntary Termination. Executive may voluntarily terminate Executive’s employment for any reason upon 30 days’ prior written notice.
In such event, after the effective date of such termination, except as provided in Section 2.2 with respect to a resignation for Good Reason, no further payments shall be due under this Agreement, except that Executive shall be entitled to any
benefits accrued in accordance with the terms of any applicable benefit plans and programs of the Company. 
  

 4 

 2.5 Disability. The Company may terminate Executive’s employment if Executive has been unable
to perform the material duties of Executive’s employment for a period of 90 days in any 12-month period because of physical or mental injury or illness (“Disability”); provided, however, that the Company shall continue to pay
Executive’s Base Salary until the Company acts to terminate Executive’s employment. Executive agrees, in the event of a dispute under this Section 2.5 relating to Executive’s Disability, to submit to a physical examination by a
licensed physician jointly selected by the Board and Executive. If the Company terminates Executive’s employment for Disability, no further payments shall be due under this Agreement, except that Executive shall be entitled to any benefits
accrued in accordance with the terms of any applicable benefit plans and programs of the Company. 
 2.6 Death. If Executive dies
while employed by the Company, the Company shall pay to Executive’s executor, legal representative, administrator or designated beneficiary, as applicable, any benefits accrued under the Company’s benefit plans and programs. Otherwise, the
Company shall have no further liability or obligation under this Agreement to Executive’s executors, legal representatives, administrators, heirs or assigns or any other person claiming under or through Executive. 
 2.7 Cause. The Company may terminate Executive’s employment at any time for Cause (as defined in Section 2.9) upon written notice to
Executive, in which event all payments under this Agreement shall cease. Executive shall be entitled to any benefits accrued before Executive’s termination in accordance with the terms of any applicable benefit plans and programs of the
Company. 
 2.8 Notice of Termination. Any termination of Executive’s employment shall be communicated by a written notice of
termination to the other party hereto given in accordance with Section 11. The notice of termination shall (i) indicate the specific termination provision in this Agreement relied upon, (ii) briefly summarize the facts and
circumstances deemed to provide a basis for a termination of employment and the applicable provision hereof, and (iii) specify the termination date in accordance with the requirements of this Agreement. 
 2.9 Definitions. 
 (a)
“Cause” shall mean any of the following grounds for termination of Executive’s employment: 
 (i) Executive shall have
been convicted of, or entered a plea of guilty to, a felony, 
 (ii) Executive intentionally and continually fails to perform
Executive’s reasonably assigned material duties to the Company (other than a failure resulting from Executive’s incapacity due to physical or mental illness), which failure has continued for a period of at least 30 days after a written
notice of demand for substantial performance, signed by a duly authorized officer of the Company, has been delivered to Executive specifying the manner in which Executive has failed substantially to perform, 
  

 5 

 (iii) Executive engages in willful misconduct in the performance of Executive’s duties, or

 (iv) Executive materially breaches Section 4, 5, 6 or 7 below. 
 (b) “Change of Control” as used herein, a “Change of Control” shall be deemed to have occurred if: 
 (i) Any “person” (as such term is used in sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”)) becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities of the
Company; provided that a Change of Control shall not be deemed to occur as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the stockholders of the Company, immediately prior to the transaction,
will beneficially own, immediately after the transaction, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the parent corporation would be entitled in the election of directors; or 
 (ii) The consummation of (A) a merger or consolidation of the Company with another corporation where the stockholders of the Company, immediately
prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the surviving corporation would be entitled
in the election of directors, (B) a sale or other disposition of all or substantially all of the assets of the Company, or (C) a liquidation or dissolution of the Company. 
 (iii) After the Effective Date, directors are elected such that a majority of the members of the Board shall have been members of the Board for less
than two years, unless the election or nomination for election of each new director who was not a director at the beginning of such two-year period was approved by a vote of at least two-thirds of the directors then still in office who were
directors at the beginning of such period. 
 (c) “Good Reason” shall mean the occurrence of any of the following events or
conditions, unless Executive has expressly consented in writing thereto, or except as a result of Executive’s physical or mental incapacity or as described in the last sentence of this subsection (c): 
 (i) a reduction in Executive’s Base Salary; 
 (ii) a substantial reduction of Executive’s duties and responsibilities hereunder; or 
 (iii) the Company requires that
Executive’s principal office location be moved to a location more than 50 miles from Executive’s principal office location immediately before the change. 
  

 6 

 Notwithstanding the foregoing, Executive shall not have Good Reason for termination unless Executive gives written notice
of termination for Good Reason within 15 days after the event giving rise to Good Reason occurs and the Company does not correct the action or failure to act that constitutes the grounds for Good Reason, as set forth in Executive’s notice of
termination, within 30 days after the date on which Executive gives written notice of termination. 
 3. Non-Exclusivity of Rights. Nothing in this
Agreement shall prevent or limit Executive’s continuing or future participation in or rights under any benefit, bonus, incentive or other plan or program provided by the Company and for which Executive may qualify; provided, however, that if
Executive becomes entitled to and receives the payments provided for in Section 2 of this Agreement, Executive hereby waives Executive’s right to receive payments under any severance plan or similar program applicable to all employees of the
Company. 
 4. Confidentiality. Executive agrees that Executive’s services to the Company and its subsidiaries and any successors or assigns
(collectively, the “Employer”) were and are of a special, unique and extraordinary character, and that Executive’s position places Executive in a position of confidence and trust with the Employer’s customers and employees.
Executive also recognizes that Executive’s position with the Employer will give Executive substantial access to Confidential Information (as defined below), the disclosure of which to competitors of the Employer would cause the Employer to
suffer substantial and irreparable damage. Executive recognizes, therefore, that it is in the Employer’s legitimate business interest to restrict Executive’s use of Confidential Information for any purposes other than the discharge of
Executive’s employment duties at the Employer, and to limit any potential appropriation of Confidential Information by Executive for the benefit of the Employer’s competitors and to the detriment of the Employer. Accordingly, Executive
agrees as follows: 
 (a) Executive will not at any time, whether during or after the termination of Executive’s employment, reveal to
any person or entity any of the trade secrets or confidential information of the Employer or of any third party which the Employer is under an obligation to keep confidential (including but not limited to trade secrets or confidential information
respecting inventions, products, designs, methods, know-how, techniques, systems, processes, software programs, works of authorship, customer lists, projects, plans and proposals) (“Confidential Information”), except as may be required in
the ordinary course of performing Executive’s duties as an employee of the Employer, and Executive shall keep secret all matters entrusted to Executive and shall not use or attempt to use any such information in any manner which may injure or
cause loss or may be calculated to injure or cause loss whether directly or indirectly to the Employer. 
 (b) The above restrictions shall
not apply to: (i) information that at the time of disclosure is in the public domain through no fault of Executive; (ii) information received from a third party outside of the Employer that was disclosed without a breach of any
confidentiality obligation; (iii) information approved for release by written authorization of the Employer; or (iv) information that may be required by law or an order of any court, agency or proceeding to be disclosed; provided Executive
shall provide the Employer notice of any such required disclosure once Executive has knowledge of it and will help the Employer to the extent reasonable to obtain an appropriate protective order. 
  

 7 

 (c) Further, Executive agrees that during Executive’s employment Executive shall not take, use or
permit to be used any notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, data, documentation or other materials of any nature relating to any matter within the scope of the business of the Employer or
concerning any of its dealings or affairs otherwise than for the benefit of the Employer. Executive further agrees that Executive shall not, after the termination of Executive’s employment, use or permit to be used any such notes, memoranda,
reports, lists, records, drawings, sketches, specifications, software programs, data, documentation or other materials, it being agreed that all of the foregoing shall be and remain the sole and exclusive property of the Employer and that,
immediately upon the termination of Executive’s employment, Executive shall deliver all of the foregoing, and all copies thereof, to the Employer, at its main office. 
 (d) Executive agrees that upon the termination of Executive’s employment with the Employer, Executive will not take or retain without written
authorization any documents, files or other property of the Employer, and Executive will return promptly to the Employer any such documents, files or property in Executive’s possession or custody, including any copies thereof maintained in any
medium or format. Executive recognizes that all documents, files and property which Executive has received and will receive from the Employer, including but not limited to scientific research, customer lists, handbooks, memoranda, product
specifications, and other materials (with the exception of documents relating to benefits to which Executive might be entitled following the termination of Executive’s employment with the Employer), are for the exclusive use of the Employer and
employees who are discharging their responsibilities on behalf of the Employer, and that Executive has no claim or right to the continued use, possession or custody of such documents, files or property following the termination of Executive’s
employment with the Employer. 
 5. Intellectual Property. 
 (a) If at any time or times during Executive’s employment Executive shall (either alone or with others) make, conceive, discover or reduce to practice any invention, modification, discovery, design, development,
improvement, process, software program, work of authorship, documentation, formula, data, technique, know-how, secret or intellectual property right whatsoever or any interest therein (whether or not patentable or registrable under copyright or
similar statutes or subject to analogous protection) (herein called “Developments”) that (i) relates to the business of the Employer or any customer of or supplier to the Employer or any of the products or services being developed,
manufactured or sold by the Employer or which may be used in relation therewith, (ii) results from tasks assigned to Executive by the Employer or (iii) results from the use of premises or personal property (whether tangible or intangible)
owned, leased or contracted for by the Employer, such Developments and the benefits thereof shall immediately become the sole and absolute property of the Employer and its assigns, and Executive shall promptly disclose to the Employer (or any
persons designated by it) each such Development, and Executive hereby assigns any rights Executive may have or acquire in the Developments and benefits and/or rights resulting therefrom to the Employer and its assigns without further compensation
and shall communicate, without cost or delay, and without publishing the same, all available information relating thereto (with all necessary plans and models) to the Employer. 
  

 8 

 (b) Upon disclosure of each Development to the Employer, Executive will, during Executive’s
employment and at any time thereafter, at the request and cost of the Employer, sign, execute, make and do all such deeds, documents, acts and things as the Employer and its duly authorized agents may reasonably require: 
 (i) to apply for, obtain and vest in the name of the Employer alone (unless the Employer otherwise directs) letters patent, copyrights or other analogous
protection in any country throughout the world and when so obtained or vested to renew and restore the same; and 
 (ii) to defend any
opposition proceedings in respect of such applications and any opposition proceedings or petitions or applications for revocation of such letters patent, copyright or other analogous protection. 
 (c) In the event the Employer is unable, after reasonable effort, to secure Executive’s signature on any letters patent, copyright or other
analogous protection relating to a Development, whether because of Executive’s physical or mental incapacity or for any other reason whatsoever, Executive hereby irrevocably designates and appoints the Employer and its duly authorized officers
and agents as Executive’s agent and attorney-in-fact, to act for and on Executive’s behalf and stead to execute and file any such application or applications and to do all other lawfully permitted acts to further the prosecution and
issuance of letter patents, copyright and other analogous protection thereon with the same legal force and effect as if executed by Executive. 
 6.
Non-Competition. While Executive is employed at the Employer and for a period of one year after termination of Executive’s employment (for any reason whatsoever, whether voluntary or involuntarily), Executive will not, without the prior
written approval of the Board, whether alone or as a partner, officer, director, consultant, agent, employee or stockholder of any company or other commercial enterprise, directly or indirectly engage in any business or other activity in the United
States or Canada which competes with the Employer in the sale of the pharmaceutical or other products being manufactured, marketed, distributed or developed by the Employer while Executive is employed by Employer and at the time of termination of
such employment. The foregoing prohibition shall not prevent Executive’s employment or engagement after termination of Executive’s employment by any company or business organization, as long as the activities of any such employment or
engagement, in any capacity, do not involve work on matters related to the products being developed, manufactured, or marketed by the Employer at the time of termination of Executive’s employment. Executive shall be permitted to own securities
of a public company not in excess of five percent of any class of such securities and to own stock, partnership interests or other securities of any entity not in excess of five percent of any class of such securities and such ownership shall not be
considered to be in competition with the Employer. 
 7. Non-Solicitation. 
 (a) While Executive is employed at the Employer and for a period of one (1) year after termination of such employment (for any reason, whether
voluntary or involuntarily), Executive agrees that Executive will not: 
  

 9 

 (i) directly or indirectly solicit, entice or induce any customer to become a customer of any other
person, firm or corporation with respect to products then sold or under development by the Employer or to cease doing business with the Employer, and Executive shall not approach any such person, firm or corporation for such purpose or authorize or
knowingly approve the taking of such actions by any other person; or 
 (ii) directly or indirectly solicit or recruit any employee of the
Employer to work for a third party other than the Employer (excluding newspaper or similar print or electronic solicitations of general circulation). 
 (b) This Section 7 does not apply to any general solicitation not focused to any group of customers itemized on a customer list of the Employer. 
 8. General Provisions. 
 (a) Executive acknowledges and agrees that the type and periods of
restrictions imposed in Sections 4, 5, 6 and 7 of this Agreement are fair and reasonable, and that such restrictions are intended solely to protect the legitimate interests of the Employer, rather than to prevent Executive from earning a livelihood.
Executive recognizes that the Employer competes worldwide, and that Executive’s access to Confidential Information makes it necessary for the Employer to restrict Executive’s post-employment activities in any market in which the Employer
competes, and in which Executive’s access to Confidential Information and other proprietary information could be used to the detriment of the Employer. In the event that any restriction set forth in this Agreement is determined to be overbroad
with respect to scope, time or geographical coverage, Executive agrees that such a restriction or restrictions should be modified and narrowed, either by a court or by the Employer, so as to preserve and protect the legitimate interests of the
Employer as described in this Agreement, and without negating or impairing any other restrictions or agreements set forth herein. 
 (b)
Executive acknowledges and agrees that if Executive should breach any of the covenants, restrictions and agreements contained herein, irreparable loss and injury would result to the Employer, and that damages arising out of such a breach may be
difficult to ascertain. Executive therefore agrees that, in addition to all other remedies provided at law or at equity, the Employer shall be entitled to have the covenants, restrictions and agreements contained in Sections 4, 5, 6, and 7
specifically enforced (including, without limitation, by temporary, preliminary, and permanent injunctions and restraining orders) by any state or federal court in the Commonwealth of Pennsylvania having equity jurisdiction and Executive agrees to
subject Executive to the jurisdiction of such court. 
 (c) Executive agrees that if the Employer fails to take action to remedy any breach
by Executive of this Agreement or any portion of the Agreement, such inaction by the Employer shall not operate or be construed as a waiver of any subsequent breach by Executive of the same or any other provision, agreement or covenant. 

(d) Executive acknowledges and agrees that the payments and benefits to be provided to Executive under this Agreement are provided as consideration
for the covenants in Sections 4, 5, 6, and 7 hereof. 
  

 10 

 9. Survivorship. The respective rights and obligations of the parties under this Agreement shall survive any
termination of Executive’s employment to the extent necessary to the intended preservation of such rights and obligations. 
 10. Mitigation.
Executive shall not be required to mitigate the amount of any payment or benefit provided for in this Agreement by seeking other employment or otherwise and there shall be no offset against amounts due Executive under this Agreement on account of
any remuneration attributable to any subsequent employment that Executive may obtain. 
 11. Notices. All notices and other communications required or
permitted under this Agreement or necessary or convenient in connection herewith shall be in writing and shall be deemed to have been given when hand delivered or mailed by registered or certified mail, as follows (provided that notice of change of
address shall be deemed given only when received): 
 If to the Company, to: 
 Auxilium Pharmaceuticals, Inc. 
 Norriton
Office Center 
 160 West Germantown Pike 
 Norristown, PA 19401 
 If to Executive, to: 
 Ed Kessig 
 7 Scenic Way 
 Middletown, NJ 07748 
 or to such other names or addresses as the Company or Executive, as the case may be, shall designate
by notice to each other person entitled to receive notices in the manner specified in this Section. 
 12. Contents of Agreement; Amendment and
Assignment. 
 (a) This Agreement sets forth the entire understanding between the parties hereto with respect to the subject matter hereof
and supercedes any and all prior agreements and understandings concerning Executive’s employment by the Company, including that certain offer letter between the Company and Executive, dated as of January 24, 2005, and cannot be changed,
modified, extended or terminated except upon written amendment approved by the Board and executed on its behalf by a duly authorized officer and by Executive. 
 (b) All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, executors, administrators, legal representatives, successors and
assigns of the parties hereto, except that the duties and responsibilities of Executive under this Agreement are of a personal nature and shall not be assignable or delegatable in whole or in part by Executive. The Company shall require any
successor (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) to all or substantially all of the business or assets of the Company, within 15 days of such succession, expressly to assume and agree to perform
this Agreement in the same manner and to the same extent as the Company would be required to perform if no such succession had taken place. 
  

 11 

 13. Severability. If any provision of this Agreement or application thereof to anyone or under any circumstances
is adjudicated to be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect any other provision or application of this Agreement which can be given effect without the invalid or unenforceable provision or
application and shall not invalidate or render unenforceable such provision or application in any other jurisdiction. If any provision is held void, invalid or unenforceable with respect to particular circumstances, it shall nevertheless remain in
full force and effect in all other circumstances. 
 14. Remedies Cumulative; No Waiver. No remedy conferred upon a party by this Agreement is
intended to be exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to any other remedy given under this Agreement or now or hereafter existing at law or in equity. No delay or omission by a
party in exercising any right, remedy or power under this Agreement or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time to time and as often as may be
deemed expedient or necessary by such party in its sole discretion. 
 15. Withholding. All payments under this Agreement shall be made subject to
applicable tax withholding, and the Company shall withhold from any payments under this Agreement all federal, state and local taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation. Except as otherwise
provided by Section 2.3, Executive shall bear all expense of, and be solely responsible for, all federal, state and local taxes due with respect to any payment received under this Agreement. 
 16. Miscellaneous. This Agreement may be executed in counterparts, each of which is an original. It shall not be necessary in making proof of this Agreement or
any counterpart hereof to produce or account for any of the other counterparts. 
 17. Governing Law. This Agreement shall be governed by and
interpreted under the laws of the Commonwealth of Pennsylvania without giving effect to any conflict of laws provisions or canons of construction that construe agreements against the draftsperson. 
  

 12 

 IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have executed this Agreement as of
the date first above written. 
  

			
	AUXILIUM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Gerri A. Henwood

	Name:	 	Gerri A. Henwood
	Title:	 	Chief Executive Officer
	
	EXECUTIVE
	
	 /s/ Edward F. Kessig

	ED KESSIG

  

 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]